Review article: fungal microbiota and digestive diseases

Summary Background The role of the fungal microbiota in digestive diseases is poorly defined, but is becoming better understood due to advances in metagenomics. Aim To review the gastrointestinal fungal microbiota and its relationship with digestive diseases. Methods Search of the literature using P...

Full description

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 39; no. 8; pp. 751 - 766
Main Authors Wang, Z. K., Yang, Y. S., Stefka, A. T., Sun, G., Peng, L. H.
Format Journal Article
LanguageEnglish
Published Oxford Blackwell 01.04.2014
Subjects
Online AccessGet full text
ISSN0269-2813
1365-2036
1365-2036
DOI10.1111/apt.12665

Cover

Loading…
More Information
Summary:Summary Background The role of the fungal microbiota in digestive diseases is poorly defined, but is becoming better understood due to advances in metagenomics. Aim To review the gastrointestinal fungal microbiota and its relationship with digestive diseases. Methods Search of the literature using PubMed and MEDLINE databases. Subject headings including ‘fungal‐bacterial interactions’, ‘mycotoxins’, ‘immunity to fungi’, ‘fungal infection’, ‘fungal microbiota’, ‘mycobiome’ and ‘digestive diseases’ were used. Results The fungal microbiota is an integral part of the gastrointestinal microecosystem with up to 106 microorganisms per gram of faeces. Next‐generation sequencing of the fungal 18S rRNA gene has allowed better characterisation of the gastrointestinal mycobiome. Numerous interactions between fungi and bacteria and the complex immune response to gastrointestinal commensal or pathogenic fungi all impact on the pathophysiology of inflammatory bowel disease and other gastrointestinal inflammatory entities such as peptic ulcers. Mycotoxins generated as fungal metabolites contribute to disturbances of gastrointestinal barrier and immune functions and are associated with chronic intestinal inflammatory conditions as well as hepatocellular and oesophagogastric cancer. Systemic and gastrointestinal disease can also lead to secondary fungal infections. Fungal genomic databases and methodologies need to be further developed and will allow a much better understanding of the diversity and function of the mycobiome in gastrointestinal inflammation, tumourigenesis, liver cirrhosis and transplantation, and its alteration as a consequence of antibiotic therapy and chemotherapy. Conclusions The fungal microbiota and its metabolites impact gastrointestinal function and contribute to the pathogenesis of digestive diseases. Further metagenomic analyses of the gastrointestinal mycobiome in health and disease is needed.
Bibliography:This commissioned review article was accepted for publication after full peer‐review.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0269-2813
1365-2036
1365-2036
DOI:10.1111/apt.12665